Tatva Chintan Pharma Chem profit and loss

Latest FY26

Revenue: ₹506cr+32.2% on FY25
EBITDA: ₹93.2cr+172.3% on FY25
Net profit: ₹42.1cr+636.1% on FY25
EPS: ₹17.98+636.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	650	506	383	394	424	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	5.9	3.5	2.3	7.5	5.7
	656	509	385	401	429
	356	263	174	179	216
	7.4	6.5	3.0	3.6	4.6
	−70.9	−44.7	22.2	−8.2	5.7
	68.9	62.9	52.9	54.8	38.6
	6.7	2.9	1.3	6.5	8.4
	40.2	36.8	27.7	25.6	9.6
	162	125	96.6	96.4	98.3
	570	452	377	357	381
	127	93.2	34.2	68.2	60.6
	86.4	56.3	6.6	42.6	51.0
Profit
	85.6	57.0	7.6	43.6	48.4
	−1.3	0.0	0.0	0.0	−3.6
	84.3	57.0	7.6	43.6	44.8
	13.1	12.0	1.5	7.6	2.9
	8.3	3.0	0.3	5.6	−3.6
	21.4	15.0	1.9	13.2	−0.7
	62.9	42.1	5.7	30.4	45.5
	62.9	42.1	5.7	30.4	45.5
	2.0	3.2	0.7	0.0	0.6
	64.9	45.3	6.4	30.4	46.1
	62.9	42.1	5.7	30.4	45.5
Per share
	₹26.90	₹17.98	₹2.44	₹13.26	₹20.52
	₹26.90	₹17.98	₹2.44	₹13.26	₹20.52
Other comprehensive income — detail
	2.0	3.2	0.7	—	—
	0.6	0.2	−0.3	−0.2	−0.2
	0.2	0.1	−0.1	—	—
	—	—	—	−0.1	−0.1
	1.6	3.0	0.9	0.2	0.8
	64.9	45.3	6.4	30.4	46.1
Per share — as-filed variants
	₹26.90	₹17.98	₹2.44	₹13.26	₹20.52
	₹26.90	₹17.98	₹2.44	₹13.26	₹20.52
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	357	281	184	219	198
	54.9%	55.6%	48.0%	55.7%	46.6%
Adjusted (ex-exceptional items) — derived
	85.6	57.0	7.6	43.6	48.4
	−1.3	0.0	0.0	0.0	−3.6
	63.9	42.1	5.7	30.4	49.1
	₹27.32	₹17.98	₹2.44	₹13.26	₹22.14

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TATVA₹1,614.80

Tatva Chintan Pharma Chem Limited

· Chemicals

Annual Quarterly₹ CrorePeersVISHNU JUBLCPL KIRIINDUS FOSECOIND CHEMPLASTS DDEVPLSTIK GUJALKALI YASHOMcap ₹3,777 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	423.6	393.5	382.7	505.9	649.9
Other Income	5.7	7.5	2.3	3.5	5.9
Total Income	429.4	401.0	385.0	509.4	655.8
Expenses
+ Cost of Materials Consumed	215.8	178.8	173.8	262.8	356.3
+ Purchases of Stock-in-Trade	4.6	3.6	3.0	6.5	7.4
+ Changes in Inventories	5.7	-8.2	22.2	-44.7	-70.9
+ Employee Benefit Expense	38.6	54.8	52.9	62.9	68.9
+ Finance Costs	8.4	6.5	1.3	2.9	6.7
+ Depreciation & Amortisation	9.6	25.6	27.7	36.8	40.2
+ Other Expenses	98.3	96.4	96.6	125.2	161.5
Total Expenses	381.0	357.4	377.5	452.4	570.2
EBITDA	60.6	68.2	34.2	93.2	126.6
EBIT	51.0	42.6	6.6	56.3	86.4
Profit
PBT before Exceptional Items	48.4	43.6	7.6	57.0	85.6
+ Exceptional Items	-3.6	0.0	0.0	0.0	-1.3
Pretax Income	44.8	43.6	7.6	57.0	84.3
+ Current Tax	2.9	7.6	1.5	12.0	13.1
+ Deferred Tax	-3.6	5.6	0.3	3.0	8.3
Tax Expense	-0.7	13.2	1.9	15.0	21.4
Net Income	45.5	30.4	5.7	42.1	62.9
+ Net Income — Continuing Ops	45.5	30.4	5.7	42.1	62.9
+ Other Comprehensive Income	0.6	0.0	0.7	3.2	2.0
Total Comprehensive Income	46.1	30.4	6.4	45.3	64.9
Net Income to Common	45.5	30.4	5.7	42.1	62.9
Per Share
Basic EPS	20.52	13.26	2.44	17.98	26.90
Diluted EPS	20.52	13.26	2.44	17.98	26.90
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.7	3.2	2.0
+ Items NOT to be Reclassified to P&L	-0.2	-0.2	-0.3	0.2	0.6
+ Tax on Items NOT to be Reclassified	—	—	-0.1	0.1	0.2
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	-0.1	—	—	—
+ Items to be Reclassified to P&L	0.8	0.2	0.9	3.0	1.6
Comprehensive Income — Owners of Parent	46.1	30.4	6.4	45.3	64.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	20.52	13.26	2.44	17.98	26.90
Diluted EPS — Continuing Operations	20.52	13.26	2.44	17.98	26.90
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	197.5	219.3	183.8	281.3	357.0
Gross Margin %	46.63	55.74	48.02	55.61	54.93
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	48.4	43.6	7.6	57.0	85.6
− Exceptional Items (reconciliation)	-3.6	0.0	0.0	0.0	-1.3
Net Income Adj (tax-effected)	49.1	30.4	5.7	42.1	63.9
EPS Adj	22.14	13.26	2.44	17.98	27.32
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	22.2	23.4	23.4	23.4	23.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.